A Study Assessing Long-Term Sustainability of Abatacept and Tumour Necrosis Factor (TNF) Inhibitors Following Treatment Failure with a Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) in Comparable Cohorts of Patients with Rheumatoid Arthritis.
Phase of Trial: Phase IV
Latest Information Update: 07 Jul 2017
At a glance
- Drugs Abatacept (Primary) ; Adalimumab; Certolizumab pegol; Etanercept; Golimumab; Infliximab
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 07 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism.